Dimerization contributes to oncogenic activation of MLL chimeras in acute leukemias
- PMID: 12957285
- DOI: 10.1016/s1535-6108(03)00188-0
Dimerization contributes to oncogenic activation of MLL chimeras in acute leukemias
Abstract
MLL is a histone methyltransferase that can be converted into an oncoprotein by acquisition of transcriptional effector domains following heterologous protein fusions with a variety of nuclear transcription factors, cofactors, or chromatin remodeling proteins in acute leukemias. Here we demonstrate an alternative mechanism for activation of MLL following fusions with proteins (AF1p/Eps15 and GAS7) that normally reside in the cytoplasm. The coiled-coil oligomerization domains of these proteins are necessary and sufficient for leukemogenic transformation induced by the respective MLL fusion proteins. Furthermore, homodimerization of MLL by synthetic dimerization modules mimics bona fide MLL fusion proteins resulting in Hox gene activation and enhanced self-renewal of hematopoietic progenitors. Our studies support an oligomerization-dependent mechanism for oncogenic conversion of MLL, presumably in part by recruitment of accessory factors through the dimerized MLL moiety of the chimeric protein.
Comment in
-
Turning on a dimer: new insights into MLL chimeras.Cancer Cell. 2003 Aug;4(2):81-3. doi: 10.1016/s1535-6108(03)00192-2. Cancer Cell. 2003. PMID: 12957280
Similar articles
-
Turning on a dimer: new insights into MLL chimeras.Cancer Cell. 2003 Aug;4(2):81-3. doi: 10.1016/s1535-6108(03)00192-2. Cancer Cell. 2003. PMID: 12957280
-
MLL-AFX requires the transcriptional effector domains of AFX to transform myeloid progenitors and transdominantly interfere with forkhead protein function.Mol Cell Biol. 2002 Sep;22(18):6542-52. doi: 10.1128/MCB.22.18.6542-6552.2002. Mol Cell Biol. 2002. PMID: 12192052 Free PMC article.
-
MLL: a histone methyltransferase disrupted in leukemia.Trends Mol Med. 2004 Oct;10(10):500-7. doi: 10.1016/j.molmed.2004.08.005. Trends Mol Med. 2004. PMID: 15464450 Review.
-
Common mechanism for oncogenic activation of MLL by forkhead family proteins.Blood. 2003 Jan 15;101(2):633-9. doi: 10.1182/blood-2002-06-1785. Epub 2002 Aug 22. Blood. 2003. PMID: 12393557
-
Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins.Oncogene. 2001 Sep 10;20(40):5695-707. doi: 10.1038/sj.onc.1204639. Oncogene. 2001. PMID: 11607819 Review.
Cited by
-
Deregulation of the HOXA9/MEIS1 axis in acute leukemia.Curr Opin Hematol. 2016 Jul;23(4):354-61. doi: 10.1097/MOH.0000000000000245. Curr Opin Hematol. 2016. PMID: 27258906 Free PMC article. Review.
-
Inactivation of PBX3 and HOXA9 by down-regulating H3K79 methylation represses NPM1-mutated leukemic cell survival.Theranostics. 2018 Jul 30;8(16):4359-4371. doi: 10.7150/thno.26900. eCollection 2018. Theranostics. 2018. PMID: 30214626 Free PMC article.
-
A CALM-derived nuclear export signal is essential for CALM-AF10-mediated leukemogenesis.Blood. 2013 Jun 6;121(23):4758-68. doi: 10.1182/blood-2012-06-435792. Epub 2013 Mar 13. Blood. 2013. PMID: 23487024 Free PMC article.
-
Translocations in epithelial cancers.Biochim Biophys Acta. 2009 Dec;1796(2):201-15. doi: 10.1016/j.bbcan.2009.04.005. Epub 2009 May 4. Biochim Biophys Acta. 2009. PMID: 19406209 Free PMC article. Review.
-
miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia.Nat Commun. 2012 Feb 21;3:688. doi: 10.1038/ncomms1681. Nat Commun. 2012. PMID: 22353710 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous